Early breast cancer: indication of a minor additional clinical benefit of adjuvant therapy with olaparib

1 December 2022 - Adjuvant treatment with olaparib can prolong life and prevent recurrence in early breast cancer. However, it ...

Read more →

Advanced cervical cancer: pembrolizumab prolongs life

2 November 2022 - There is a hint of a major added benefit compared to chemotherapy with cisplatin or carboplatin, each ...

Read more →

Evidence based drug delivery for rare diseases: the role of digitisation

25 October 2022 - Digitisation has potential when it comes to making clinical development for the care of rare diseases more ...

Read more →

Germany significantly tightens drug pricing and reimbursement laws

26 October 2022 - The German regulation of pricing and reimbursement of pharmaceuticals is probably one of the most complicated legal ...

Read more →

COVID-19: nirmatrelvir/ritonavir reduces the risk of a severe course in patients at risk

4 October 2022 - However, due to contra-indications and interactions, the combination of active ingredients is not suitable for all patients ...

Read more →

Palbociclib combination in advanced breast cancer: again only disadvantages

5 October 2022 - For post-menopausal women with hormone receptor positive, HER2 negative breast cancer in the first line, there is ...

Read more →

Registry-based randomised trials: the best of both worlds?

15 September 2022 - IQWiG authors present the advantages and disadvantages of study designs that combine explanatory and pragmatic aspects. ...

Read more →

Is IQWiG's 15% threshold universally applicable in assessing the clinical relevance of patient reported outcomes changes? An ISPOR Special Interest Group report.

8 September 2022 - To assess the clinical relevance of patient reported outcomes, a response threshold of ≥ 15% of the ...

Read more →

Availability of new medicines in the US and Germany (2004 - 2018)

30 August 2022 - In this cohort study comparing 599 medicine approvals in the US and Germany between 2004 and 2018, ...

Read more →

IQWiG annual report for 2021 is available

17 August 2022 - The IQWiG has published its 2021 annual report today.  ...

Read more →

Advanced oesophageal carcinoma: nivolumab in combination with chemotherapy or ipilimumab prolongs life compared to chemotherapy alone

1 August 2022 - The additional clinical benefit cannot be quantified because the data on health status and health-related quality ...

Read more →

German Government announces bill to drastically slash drug reimbursement

19 July 2022 - On 8 July 2022, the German Health Ministry has officially shared the second edition of a new ...

Read more →

Post-menopausal osteoporosis: advantages of teriparatide over risedronate sodium

2 June 2022 - Preliminary report on the comparative benefit assessment of bisphosphonates, teriparatide and denosumab is available. Please submit ...

Read more →

Application accompanying data collection in the case of market access for several active substances in a class: IQWiG presents a concept

27 May 2022 - The institute recommends platform studies under a master's protocol. ...

Read more →

G-BA certifies active ingredients against breast and oesophageal cancer as having a high additional benefit

19 May 2022 - The Federal Joint Committee (G-BA) has rated the patient-relevant additional benefit of two active ingredients for cancer ...

Read more →